SCHEMBL945291

SCHEMBL945291

CC(C)NC(=O)N1CCC(CCOc2ccc(C(=O)NCC3C4CC5CC3CC(O)(C5)C4)cc2)CC1

nearest known ligand 0.41

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 1/20 0.39
HRH3 Q9Y5N1 2/20 0.39
CHRM4 P08173 1/20 0.39
GPR119 Q8TDV5 2/20 0.39
HRH2 P25021 1/20 0.39
HRH1 P35367 1/20 0.39
CHRM2 P08172 1/20 0.38
TEAD1 P28347 1/20 0.37
TEAD3 Q99594 1/20 0.37
DGAT1 O75907 1/20 0.37
IDH1 O75874 1/20 0.36
HPGD P15428 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL238435 0.92 GPR119 (0.44) EPHX2HRH3CHRM4GPR119HRH2
SCHEMBL946687 0.89 IDH1 (0.45) EPHX2HRH3GPR119IDH1
SCHEMBL3722073 0.85 ITGB3 (0.40) EPHX2GPR119TEAD1TEAD3DGAT1
SCHEMBL945292 0.85 GPR119 (0.47) HRH3GPR119HRH2HRH1CHRM2
SCHEMBL14097623 0.83 GPR119 (0.39) EPHX2HRH3CHRM4GPR119HRH2
SCHEMBL1168816 0.79 HSD11B1 (0.45) IDH1
SCHEMBL14097603 0.79 GPR119 (0.43) HRH3GPR119HRH2HRH1CHRM2
SCHEMBL946688 0.78 MAPT (0.43) EPHX2IDH1
SCHEMBL238436 0.78 GPR119 (0.44) GPR119HRH2HRH1
SCHEMBL942754 0.77 HRH2 (0.50) HRH3GPR119HRH2HRH1TEAD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110003852-A1 N-ADAMANTYL BENZAMIDES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE HIGH POINT PHARMACEUTICALS, LLC 2011-01-06 US claimed
US-20110003852-A1 N-ADAMANTYL BENZAMIDES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE HIGH POINT PHARMACEUTICALS, LLC 2011-01-06 US disclosed
US-20110003856-A1 N-ADAMANTYL BENZAMIDES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE HIGH POINT PHARMACEUTICALS, LLC 2011-01-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110003856-A1 N-ADAMANTYL BENZAMIDES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE HSD11B1, HSD3B1, HSD17B1 EPHX2 1278/4885HRH3 498/4885CHRM4 4776/4885
US-20110003852-A1 N-ADAMANTYL BENZAMIDES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE HSD11B1, HSD3B1, HSD17B1 EPHX2 1278/4885HRH3 498/4885CHRM4 4776/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.